Table 1.
Characteristics of included articles in the systematic review
| Author | Year | Region | Type of cancer | Sample | Duration of study | Dosage of the drug | Animal model/cell line | Phase | Main results |
|---|---|---|---|---|---|---|---|---|---|
| Karthikeyan et al. (30) | 2013 | India | Oral | 24 | 14 weeks | 250 mg/kg b.w | Male golden Syrian hamsters | I and II | Chrysin has the potential to delay rather than inhibit tumor formation |
| Yu et al. (35) | 2013 | USA | Thyroid | 18 | 3 weeks |
75 mg/kg b.w 25, 50 & 75 µM/ml |
Male nude mice HTh7; KAT18 cell lines |
NA | Chrysin inhibits tumor growth in ATC both in vitro and in vivo |
| Liu et al. (42) | 2013 | Korea | Skin | 18 | 1 weeks | 10 µM | JB6 P | G0/G1, S, or G2/M | Chrysin is an effective agent for inhibiting neoplastic transformation and tumor growth |
| Yang et al. (43) | 2014 | China | Breast | 15 | NA | 5, 10, and 20 µM | TNBC | NA | Chrysin exerts antimetastatic activities |
| Lirdpr-apamongkol et al. (44) | 2013 | Thailand | Breast | 10 | 6 weeks | 10–100 µg/ml | 4T1cell lines | NA | Chrysin can control metastatic progression and inhibited STAT3 activation |
| Kasala et al. (45) | 2016 | India | Lung | 6 | 16 weeks | 250 mg/kg b.w | Male Swiss albino mice | NA | Chrysin maintained cellular homeostasis |
| Brechbuhl et al. (46) | 2012 | USA | Lung | 4 cell lines | NA | 5–25 µM | A549; H157; H460; H1975 | phase I | Chrysin worked synergistically with doxorubicin to induce cancer cell death |
| Shao et al. (34) | 2012 | China | Lung | NA | 1 weeks | 1 µm | A549 | NA | That activation of AMPK by chrysin contributes to Akt suppression, growth inhibition, and apoptosis in human lung cancer cells |
| Li et al. (47) | 2015 | China | Colorectal | NA | NA | 10–40 µM | HCT-116; HepG2; Hep 3B | G1 phase | That combination of chrysin and cisplatin is a promising strategy for chemotherapy of human cancers |
| Fu et al. (33) | 2007 | China | Renal | 8 | 4 weeks | 10, 30, and 50 µM | DU145 | NA | Chrysin can be a potent inhibitor of angiogenesis and tumorigenesis |
| Lim et al. (48) | 2017 | Korea | Lung | 6 | 4 weeks | 25 µM | A549 | NA | Chrysin extirpates DTX-induced edema as an adverse effect |
| Rehman et al. (49) | 2013 | India | Renal | 6 | 16 weeks | 20 and 40 mg/kg b.w | Male albino Wistar rat | Phase II | Chrysin as an effective chemopreventive agent having the capability to obstruct DEN-initiated and Fe-NTA-promoted renal cancer in the rat model |
| Khan et al. (50) | 2010 | India | Hepatic | 10 | 11 Weeks | 250 mg/kg b.w | Male albino Wistar rat | NA | Mechanism of action of chrysin occurs through decrease in cell proliferation, induction of cell death by apoptosis and reduction of inflammation |
| Zheng et al. (51) | ,2003 | China | Colorectal | NA | 1 Weeks | NA | SGC-7901 and HT-29 cells | NA | 8-bromo-5-hydroxy-7-methoxychrysin was identified as the most potent anti-HT-29 tumor cells and 5,7-dimethoxy-8-iodochrysin showed the most significant activity against SGC-7901 tumor cells |
| Maruhashi et al. (52) | 2019 | Japan | Lung | 6 | 2 Weeks | 100 mg | SCC and RERF-LC-AL cell | Plateau phase | Chrysin may be useful as an adjuvant chemotherapy in lung SCC |
| Lee et al. (53) | 2021 | Korea | Gastric | NA | NA | 25 µM | AGS/FR cell | G2/M phas | Chrysin potentiates the anticancer effect of 5-FU and may be utilized for the treatment of 5-FU-resistant gastric cancer |
| Bahadori et al. (54) | 2016 | Iran | Colon | 5 | 6 Weeks | 0.5, 1, 2, 4, 8, and 10 mg kg−1 | Male BALB/c mice | NA | Chrysin as an efficient apoptosis-based therapeutic agent against colon cancer |
| Song et al. (55) | 2019 | Korea | Colon | 3 | NA | 1 mg/ml | HT-29 cell | NA | Chrysin may have efficacy as an anticancer candidate for colon cancer therapy |
| Sun et al. (56) | 2012 | China | Breast | 9 | 42 days | 10, 20, and 40 μM | Xenograft animal model | G0/G1 phase |
Orally administered Chrysin potently inhibits tumor growth in mice |
| Chen et al. (57) | 2020 | China | Esophageal | 5 | 5 Weeks | 10, 25, or 50 mg/kg/day | ESCC cells | NA | Chrysin exerts its anticancer effect in ESCC cells via disruption of the assembly of DGKα/FAK complex and resultant blockage of the FAK/AKT signaling pathways |
| Zhang et al. (58) | 2004 | China | Cervical | NA | 1 Week | NA | Hela cells | NA | Chrysin may be a new potential anti-cancer drug for therapy of human cervical carcinoma |
ESCC esophageal squamous cell carcinoma, SCC squamous cell carcinoma, 5-FU 5-fluorouracil, DTX docetaxel, AMPK AMP-activated protein kinase, NA not available